Author

Max Matonhodze

Observed names: M Matonhodze, M. Matonhodze, Matonhodze, Max

Institutions: Walsall Manor Hospital, Walsall Healthcare NHS Trust

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Public Health England, National Institute for Health and Care Research, University of Oxford, Public Health Scotland, National Records of Scotland, Nepal Health Research Council, Walsall Manor Hospital, Walsall Healthcare NHS Trust, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia

OpenAlex ID: A5068343683

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Post pulmonary embolism syndrome: a common, underdiagnosed complication that is not well recognised

2019 · Alexander Sanders, Max Matonhodze · BMJ Case Reports · 3

P205 Real world outcomes of Tezepelumab in obese and non-obese severe asthmatics

2025 · C Ajayi, S Khan, et al. · 1

Uncommon condition mimicking non-resolving pneumonia and malignancy on radiography that improves dramatically with a course of steroids

2016 · Alexander Sanders, Max Matonhodze · BMJ Case Reports · 1

P206 Effectiveness of tezepelumab treatment in patients with severe asthma: real world outcomes from a severe asthma network

2025 · S Khan, M Drew, et al.

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Works count: 16

Citation count: 2,239

H-index: 9

I10-index: 9